Nuclear protein as a prognostic factor of growth activity in prostatic adenocarcinoma

被引：1

作者：

Dohle, GR ^{[1
]}

Beekhuis, JAM ^{[1
]}

vanSteenbrugge, GJ ^{[1
]}

Schroder, FH ^{[1
]}

Tanke, HJ ^{[1
]}

机构：

[1] LEIDEN STATE UNIV,DEPT CYTOCHEM & CYTOMETRY,LEIDEN,NETHERLANDS

来源：

UROLOGICAL RESEARCH | 1996年 / 24卷 / 05期

关键词：

nuclear protein; DNA; prostatic adenocarcinoma; cell proliferation;

D O I：

10.1007/BF00304773

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

The value of nuclear protein (NP) as a prognostic parameter in prostatic adenocarcinoma was investigated. The NP and DNA contents of two prostatic tumour lines with a well-documented hormonal dependency (PC-82, PC-EW) were compared to the NP and DNA contents of two xenografts with only partial or no response to androgen deprivation (LNCaP, PC-133). After hormonal treatment the PC-82 and PC-EW tumours showed a significant decrease in the NP/DNA ratio, which coincided with a decrease in the proliferative activity [anti-bromodeoxyuridine (BRDU) antibody-labelling index] of the same specimens. In the fast-growing LNCaP tumour an increased percentage of cells with high NP and DNA contents was found. The tumours PC-82, PC-EW, and PC-133 with lower proliferative activity showed lower nuclear protein and DNA contents. In a pilot study of 20 prostatic biopsies the amount of nuclear protein and DNA in grade 1-3 tumours as well as in dysplasia was measured. Statistically significant differences (P < 0.002) were found between grade 1 and grade 3 tumours. The mean NP/DNA ratio was increased in high-grade malignancies. Nuclear protein appeared to be a potential parameter in predicting growth activity in prostatic carcinoma.

引用

页码：251 / 255

页数：5

共 24 条

[1]

AUER G, 1983, ANAL QUANT CYTOL, V5, P1

[2]

ANDROGEN-DEPENDENT GROWTH-REGULATION OF AND RELEASE OF SPECIFIC PROTEIN(S) BY THE ANDROGEN RECEPTOR CONTAINING HUMAN-PROSTATE TUMOR-CELL LINE LNCAP [J].

BERNS, EMJJ ;

DEBOER, W ;

MULDER, E .

PROSTATE, 1986, 9 (03) :247-259

[3]

Byar D P, 1988, NCI Monogr, P165

[4]

DIAMOND DA, 1982, J UROLOGY, V128, P792

[5]

FRANZEN S, 1960, Br J Urol, V32, P193, DOI 10.1111/j.1464-410X.1960.tb03763.x

[6]

HOEHN W, 1980, Prostate, V1, P95, DOI 10.1002/pros.2990010113

[7]

PROSTATIC ADENOCARCINOMA PC-EW, A NEW HUMAN-TUMOR LINE TRANSPLANTABLE IN NUDE-MICE [J].

HOEHN, W ;

WAGNER, M ;

RIEMANN, JF ;

HERMANEK, P ;

WILLIAMS, E ;

WALTHER, R ;

SCHRUEFFER, R .

PROSTATE, 1984, 5 (04) :445-452

[8]

HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809

[9]

ISAACS JT, 1978, CANCER RES, V38, P4353

[10]

MORBERGER B, 1989, ANAL CELL PATHOL, V2, P15

← 1 2 3 →